neratinib + capecitabine + lapatinib
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2+ Metastatic Breast Cancer (MBC)
Conditions
HER2+ Metastatic Breast Cancer (MBC)
Trial Timeline
Mar 29, 2013 → Dec 9, 2019
NCT ID
NCT01808573About neratinib + capecitabine + lapatinib
neratinib + capecitabine + lapatinib is a phase 3 stage product being developed by Puma Biotechnology for HER2+ Metastatic Breast Cancer (MBC). The current trial status is completed. This product is registered under clinical trial identifier NCT01808573. Target conditions include HER2+ Metastatic Breast Cancer (MBC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01808573 | Phase 3 | Completed |
Competing Products
6 competing products in HER2+ Metastatic Breast Cancer (MBC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab | Novartis | Phase 3 | 77 |
| NJH395 | Novartis | Phase 1 | 33 |
| Tucatinib | Pfizer | Phase 1 | 32 |
| Tucatinib + Trastuzumab + Capecitabine | Pfizer | Pre-clinical | 22 |
| ZW25 (Zanidatamab) + Palbociclib + Fulvestrant | Jazz Pharmaceuticals | Phase 2 | 49 |
| Neratinib + Loperamide + Colestipol + Budesonide | Puma Biotechnology | Phase 2 | 44 |